Statins Linked to Lower PVR Risk After Retinal Detachment Surgery

Statin Use Tied to Reduced Risk of PVR After Retinal Detachment Surgery

A study of nearly 55,000 eyes undergoing retinal detachment repair surgery found that patients taking statins had a 30% lower risk of developing proliferative vitreoretinopathy (PVR), a complication that can lead to recurrent detachment, according to research presented at the American Academy of Ophthalmology (AAO) 2025 Annual Meeting. The findings, led by Sidra Zafar, MD, a retina fellow at Wills Eye Hospital in Philadelphia, highlight a potential protective effect of statins beyond their well-known role in cholesterol management.

Within 90 days of surgery, 6.7% of statin users developed PVR compared to 8.2% of non-users (P < .001). At 180 days, the rates were 8.1% and 9.8%, respectively (P < .001). Despite this reduced risk, the likelihood of requiring a second operation for complex retinal detachment was similar between the two groups, at 2.9% (P = .94). The study, which analyzed data from 2015 to 2024, included 54,876 adult eyes that underwent scleral buckle procedures or vitrectomy plus scleral buckle for rhegmatogenous retinal detachment.

Statin Users Had Higher Baseline Risk Factors

Statin users in the study were older (average age 67 vs. 59) and more likely to have comorbidities such as diabetes (26% vs. 9%) and hypertension (67% vs. 33%) compared to non-users. These factors are known to increase surgical complication risks. Despite this, statin users still exhibited lower PVR rates, suggesting a possible protective role of the medication. The study identified additional risk factors for PVR, including advanced age, absence of the crystalline lens, diabetes, and smoking history.

Zafar noted that while the results are promising, the study’s retrospective design and reliance on diagnosis codes to track outcomes limit its conclusions. There’s certainly more work that needs to be done to better understand this, she said. The research builds on earlier European studies, including a Finnish study showing lower harmful protein levels in statin users after vitrectomy and a 28% lower rate of secondary vitrectomy in statin patients.

Experts Call for Further Research on Statins and Eye Surgery

Nikhil Bommakanti, MD, a vitreoretinal surgeon at Tufts Medical Center, called the study “good” and emphasized the need for randomized trials to confirm the findings. Proliferative vitreoretinopathy is one of the main problems that keeps us up at night, he said, noting that the condition can lead to vision loss. While the study’s large dataset and consistency with smaller studies are strengths, Bommakanti highlighted limitations, including the lack of data on statin dosage, duration, and adherence—factors critical for understanding the medication’s true impact.

The study also raises questions about statins’ potential anti-inflammatory mechanisms. Zafar pointed to prior evidence of statins’ protective effects in conditions like age-related macular degeneration and diabetic retinopathy, suggesting their properties might reduce PVR risk. However, she cautioned that more research is needed, including prospective trials, to establish causality and optimal treatment protocols.

Context and Implications for Clinical Practice

The findings add to a growing body of evidence exploring statins’ role in ophthalmic care. While the study does not advocate for prescribing statins solely for PVR prevention, it underscores the importance of considering patients’ medication histories during retinal surgery planning. Bommakanti noted that the field is actively investigating post-surgical interventions to reduce complications. It’s exciting to see more work being done that suggests an existing, commonly used oral medication might be helpful, he said. However, he stressed that current guidelines do not support changing clinical practice based on this single study. This is in its infancy, Zafar said, calling for more rigorous research to validate the findings and explore underlying biological mechanisms.